Vimarsana
Biggest News Aggregation in the World

Page 18 - Column Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Column Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Column Group Today - Breaking & Trending Today

A brand new nine-story building at 100 Forge in Watertown is now fully leased - Vimarsana News

A brand new nine-story building at 100 Forge in Watertown is now fully leased

Boylston Properties announces 100 Forge in Watertown is now fully leased to five life science companies.

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors - Vimarsana News

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace

A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021 - Vimarsana News

A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021

/PRNewswire/ -- A2 Biotherapeutics, Inc., "A2 Bio", is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid...

Worldwide Antibody Drug Conjugates Industry to 2030 - Key Trends and Forecasts - Vimarsana News

Worldwide Antibody Drug Conjugates Industry to 2030 - Key Trends and Forecasts

/PRNewswire/ -- The "Antibody Drug Conjugates Market by Indication, Linker, Payload, Target Antigens and Geography: Industry Trends and Global Forecasts,...

A biotech startup's hunt for elusive disease targets scores $60M for drug R&D - Vimarsana News

A biotech startup's hunt for elusive disease targets scores $60M for drug R&D

Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.